logo oncology-news

Онкология  >  Новости онкологии

При финансовой поддержке logo MSD Oncology

mTNBC: sacituzumab govitecan shows promise in IMMU-132-01

Response rate of 33.3%, median DOR of 7.7 months observed in 108 patients.